Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Obstruction of BRAFV600E transcription by complementary PNA oligomers as a means to inhibit BRAF-mutant melanoma growth.

Rothman JH, Surriga O, de Stanchina E, Vasudeva SD, Schwartz GK.

Cancer Gene Ther. 2017 Sep;24(9):401-408. doi: 10.1038/cgt.2017.34. Epub 2017 Sep 22.

PMID:
28937091
2.

MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma.

Slotkin EK, Patwardhan PP, Vasudeva SD, de Stanchina E, Tap WD, Schwartz GK.

Mol Cancer Ther. 2015 Feb;14(2):395-406. doi: 10.1158/1535-7163.MCT-14-0711. Epub 2014 Dec 17.

3.

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.

Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, Agulnik M, Schuetze SM, Reed DR, Okuno SH, Ludwig JA, Keedy V, Rietschel P, Kraft AS, Adkins D, Van Tine BA, Brockstein B, Yim V, Bitas C, Abdullah A, Antonescu CR, Condy M, Dickson MA, Vasudeva SD, Ho AL, Doyle LA, Chen HX, Maki RG.

Lancet Oncol. 2013 Apr;14(4):371-82. doi: 10.1016/S1470-2045(13)70049-4. Epub 2013 Mar 8.

4.

PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma.

Ho AL, Vasudeva SD, LaƩ M, Saito T, Barbashina V, Antonescu CR, Ladanyi M, Schwartz GK.

Cancer Res. 2012 Sep 1;72(17):4515-25. doi: 10.1158/0008-5472.CAN-12-1319. Epub 2012 Jul 10.

Supplemental Content

Loading ...
Support Center